Insider Trading & Ownership of Bryan Lawlis V

Summary
The estimated net worth of Bryan Lawlis V is at least $3,209,700 dollars as of 22 May 2025. Bryan Lawlis V is the Director of BIOMARIN PHARMACEUTICAL INC and owns shares of BIOMARIN PHARMACEUTICAL INC (BMRN) stock worth about $3.19M. Bryan Lawlis V is the Director of GERON CORP and owns shares of GERON CORP (GERN) stock worth about $15.7K.
Signature
/s/ Scott A. Samuels, Attorney-in-fact for V. Bryan Lawlis
All Insider Reports
All Insider Reports

Follow Filing Activity

Follow Bryan Lawlis V and return when a new Insider Trading filing changes the record on this page.

This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.

Quick Takeaways

  • Bryan Lawlis V has 3 issuer positions tracked on this page.
  • Estimated disclosed ownership value: $3,209,700.
  • Recent insider filing activity is available below.

What Changed

  • Largest disclosed position: BIOMARIN PHARMACEUTICAL INC ($3,194,033).
  • Past-year value change for that position: .

Why This Matters

  • This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
  • You can cross-check role, issuer, and filing chronology directly against the SEC source.

Source Evidence

Filed on Form 4

Insider ownership context is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Ownership of Bryan Lawlis V

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
BMRN BIOMARIN PHARMACEUTICAL INC Director $3,194,033 23 May 2023
GERN GERON CORP Director $15,667 +$15,667 +100% 21 May 2025
SYRE Aeglea BioTherapeutics, Inc. Director 07 Jun 2022

Insider Transactions Reported by Bryan Lawlis V:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .